Aspire Biopharma (NASDAQ:ASBP) Trading Up 10.9% – What’s Next?

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP)’s stock price traded up 10.9% during mid-day trading on Monday . The stock traded as high as $7.44 and last traded at $7.23. 27,396 shares were traded during mid-day trading, a decline of 49% from the average daily volume of 54,125 shares. The stock had previously closed at $6.52.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Aspire Biopharma has a consensus rating of “Sell”.

Aspire Biopharma Trading Up 3.9%

The business’s 50-day simple moving average is $6.20 and its two-hundred day simple moving average is $21.56. The company has a market capitalization of $9.51 million, a PE ratio of -0.06 and a beta of 0.11.

Aspire Biopharma (NASDAQ:ASBP) last announced its earnings results on Friday, May 15th. The company reported ($20.57) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million during the quarter.

Institutional Investors Weigh In On Aspire Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. CIBC Bancorp USA Inc. acquired a new position in shares of Aspire Biopharma in the 3rd quarter valued at approximately $28,000. XTX Topco Ltd grew its position in shares of Aspire Biopharma by 853.2% during the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after buying an additional 237,620 shares in the last quarter. Finally, Jane Street Group LLC grew its position in shares of Aspire Biopharma by 625.8% during the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after buying an additional 131,533 shares in the last quarter. 19.17% of the stock is currently owned by hedge funds and other institutional investors.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.